ArticleRecent patents on biotechnology2026
Article in Recent patents on biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe plant Cinnamomum tamala (Buch.-Ham.) T. Nees & C.H. Ebern. (Family: Lauraceae) is commonly known as 'tejpaat' in India, has leaves and bark reported to possess anticancer, immunomodulatory, antidiabetic, and diuretic activities. The objective of the present study was to explore the antitumor potential of the chloroform extract of Cinnamomum tamala leaves (CTCE) in BALB/c mice against Ehrlich's Carcinoma (EC).
methodsBased on preliminary in-vitro cytotoxicity studies, CTCE was selected for an in-vivo antitumor study. Anticancer activity of CTCE was evaluated in BALB/c mice against EC at the doses of 50, 100, 250, and 500 mg/kg body weight. CTCE was administered for 15 consecutive days after induction of the tumor. After 24 hours from the last administered dose and 18 hours of fasting, half of the mice were sacrificed, while the other half was kept alive to evaluate any potential for increasing the lifespan. The antitumor effect of CTCE was assessed by evaluating tumor volume, hematological parameters, and the life span of the EC-bearing host.
resultsCTCE showed a significant decrease (p<0.05) in tumor volume and increased the lifespan of EC tumor-bearing mice in a dose-dependent manner compared with the untreated group. The hematological profile, including RBC count, hemoglobin, WBC count, and DLC, was also improved upon treatment. DISCUSSION: C. tamala chloroform extract (CTCE) showed significant anticancer potential by reducing cell viability, inhibiting tumor growth, and prolonging survival without toxicity, suggesting it as a promising source of bioactive compounds for anticancer drug development.
conclusionThe results suggest that CTCE exhibits dose-dependent anticancer activity in comparison with EC control mice and demonstrates significant effects relative to doxorubicin. Its antitumor activity may be attributed to the presence of active constituents within the extract. This investigation also highlights recent advancements in intellectual property rights and patent strategies related to plant-derived anticancer agents.
Indexed as
Identifiers
41992462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.